[
  {
    "trial": "T020",
    "source": "fulltext",
    "arms": {
      "Ketamine": {"randomized": "165", "analysed": "153"},
      "Placebo (saline)": {"randomized": "165", "analysed": "155"}
    },
    "depression": [
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "mean_sd", "location": "Table 2",
       "values": {"Ketamine": {"mean": "7.5", "sd": "2.2", "n": "153"}, "Placebo (saline)": {"mean": "8.2", "sd": "2.0", "n": "155"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "count", "definition": "EPDS > 9", "location": "Table 2",
       "values": {"Ketamine": {"events": "20", "n": "153"}, "Placebo (saline)": {"events": "35", "n": "155"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 14, "form": "mean_sd", "location": "Table 2",
       "values": {"Ketamine": {"mean": "7.4", "sd": "2.0", "n": "153"}, "Placebo (saline)": {"mean": "7.8", "sd": "2.1", "n": "155"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 14, "form": "count", "definition": "EPDS > 9", "location": "Table 2",
       "values": {"Ketamine": {"events": "18", "n": "153"}, "Placebo (saline)": {"events": "26", "n": "155"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 30, "form": "mean_sd", "location": "Table 2",
       "values": {"Ketamine": {"mean": "7.3", "sd": "2.1", "n": "153"}, "Placebo (saline)": {"mean": "7.5", "sd": "2.2", "n": "155"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 30, "form": "count", "definition": "EPDS > 9", "location": "Table 2",
       "values": {"Ketamine": {"events": "16", "n": "153"}, "Placebo (saline)": {"events": "22", "n": "155"}}}
    ],
    "pain": [
      {"measure": "NRS pain at 2 days", "day": 2, "form": "mean_sd", "location": "Table 2 (NRS score, wound pain)",
       "values": {"Ketamine": {"mean": "3.0", "sd": "0.9", "n": "153"}, "Placebo (saline)": {"mean": "4.0", "sd": "1.0", "n": "155"}}},
      {"measure": "NRS score: contraction pain", "day": 2, "form": "mean_sd", "location": "Table 2 (NRS score, contraction pain)",
       "values": {"Ketamine": {"mean": "3.0", "sd": "0.9", "n": "153"}, "Placebo (saline)": {"mean": "4.1", "sd": "0.9", "n": "155"}}}
    ],
    "adverse_events": [
      {"window": "intraoperative", "time": "5 min after dosing", "location": "Table 3",
       "values": {"Ketamine": {"hallucination": "24", "dizziness": "56"}, "Placebo (saline)": {"hallucination": "0", "dizziness": "0"}}},
      {"window": "intraoperative", "time": "15 min after dosing", "location": "Table 3",
       "values": {"Ketamine": {"hallucination": "6", "dizziness": "34"}, "Placebo (saline)": {"hallucination": "0", "dizziness": "2"}}},
      {"window": "intraoperative", "time": "Out of operation room (asked before leaving the operating room)", "location": "Table 3",
       "values": {"Ketamine": {"hallucination": "1", "dizziness": "2"}, "Placebo (saline)": {"hallucination": "0", "dizziness": "1"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2019-06-26", "end": "2019-07-15"},
    "registration": {"number": "ChiCTR1900022464", "date": null},
    "note": "The ± in Tables 1-2 is not defined anywhere in the source; taken as SD. The PPD count definition is the Methods' cutoff (EPDS score > 9). The design's single pain measure is reported as two NRS scores at 2 days postpartum: wound pain is entered under the design's name and uterine contraction pain under the source's name. Table 3 gives intraoperative side effects at three assessments (5 and 15 min after dosing, and before leaving the operating room), not the number of participants with any event, so each assessment is a separate entry with its time; headache and vomiting are also in Table 3 but are not codebook categories. Randomized 165 per group and analysed 153/155 are from the Results' first paragraph."
  },
  {
    "trial": "T043",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "173", "analysed": "159"},
      "Control group": {"randomized": "173", "analysed": "160"}
    },
    "depression": [
      {"measure": "Edinburgh Depression Scale (EPDS)", "day": 4, "form": "count", "definition": "EPDS > 9", "location": "Results, Primary outcome paragraph",
       "values": {"Esketamine group": {"events": "22"}, "Control group": {"events": "37"}}},
      {"measure": "Edinburgh Depression Scale (EPDS)", "day": 42, "form": "percent", "definition": "EPDS > 9", "location": "Results, Primary outcome paragraph",
       "values": {"Esketamine group": {"percent": "17"}, "Control group": {"percent": "25"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "overall", "location": "Results, Primary outcome paragraph (percentages only)",
       "values": {"Esketamine group": {"dizziness": "17.0%", "visual": "5%", "hallucination": "3.8%"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2020-07", "end": "2023-09"},
    "registration": {"number": "ChiCTR2100053422", "date": "2021-11-20"},
    "note": "No EPDS means are printed (Figures 2-3 only). The day-4 PPD counts come from the Results text, where the esketamine count is written as the word 'Twenty-two' (entered as 22); n is not printed with them (the 13.8% and 23.1% match the analysed 159 and 160). Day 42 is given only as percentages ('17% vs 25%', esketamine first), so it is entered in a 'percent' form with no counts. NRS at 6, 12, 24 and 48 h is in Figure 4 only, with no printed values. Adverse events: the Results give only esketamine-group percentages (dizziness 17.0%, blurred vision 5% entered as visual, 'illusion' 3.8% entered as hallucination; drowsiness 3.8% is not a codebook category). Control values are only in Figure 6. They are entered as printed, with % signs, and the window is not stated. Randomized 173 per group is from the sample-size paragraph ('173 patients were randomly assigned to each group') and matches the Results' flow (173-9-4=160 and 173-8-1-5=159). Enrollment is as the Results state it ('From July 2020 to September 2023', which includes follow-up); the Methods say the study ran July 1, 2020 to July 21, 2023, with last follow-up on September 1, 2023. The registration (printed 20/11/2021) postdates the start of enrollment."
  },
  {
    "trial": "T062",
    "source": "library",
    "arms": {
      "Group S": {"randomized": null, "analysed": "33"},
      "Group C (0.9% saline)": {"randomized": null, "analysed": "32"}
    },
    "depression": [],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 3",
       "values": {"Group S": {"dizziness": "3", "hallucination": "2", "any_ae": "12"}, "Group C (0.9% saline)": {"dizziness": "2", "hallucination": "0", "any_ae": "10"}}}
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "ChiCTR2300070728", "date": null},
    "note": "Per-arm randomized numbers are not given. The text says 72 were randomized and 4 were then excluded, yet 65 were analysed (33/32); the abstract pairs '72 ... enrolled' with n = 33 and 32. PHQ-9 at baseline, 1 week and 3 months is shown only in Figure 4, with no printed values. NRS at 4 h and 24 h (rest and movement) is only in Figures 2-3. CPSP at 3 months (Table 2: 6(18.2%) vs 14(43.8%); the abstract gives 48.3% for group C) falls outside the day 1-2 window and is not entered. Rescue hydromorphone appears only as Table 1's 'Rescue analgesic (N, %)', 6(18%) vs 13(41%), with no time window, so it is not entered as day 1 or 2. Table 3's adverse-event window is not stated beyond 'postoperative nausea and vomiting' (patients were under general anaesthesia), so it is entered as postoperative. 'Dizzy(n)' is entered as dizziness and 'Total(n)' as any_ae (PONV, the other row, is not a codebook category). Registration is stated as 'before patient enrollment', with no date. No enrollment dates are given."
  },
  {
    "trial": "T069",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "150", "analysed": "148"},
      "Control group": {"randomized": "150", "analysed": "150"}
    },
    "depression": [
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": -1, "form": "mean_sd", "location": "Table (Baseline EPDS score, mean (SD)); same in Results text",
       "values": {"Esketamine group": {"mean": "4.2", "sd": "2.3", "n": "148"}, "Control group": {"mean": "4.0", "sd": "2.2", "n": "150"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "count", "definition": "EPDS ≥ 10", "location": "Results, Efficacy Outcomes",
       "values": {"Esketamine group": {"events": "34", "n": "148"}, "Control group": {"events": "53", "n": "150"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "change_difference", "location": "Results, Efficacy Outcomes",
       "estimate": "-1.17", "se": "0.44", "lower": "-2.04", "upper": "-0.31", "level": "0.95", "scale": "mean_difference", "contrast": "Esketamine group minus Control group",
       "values": {"Esketamine group": {"n": "148"}, "Control group": {"n": "150"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 14, "form": "count", "definition": "EPDS ≥ 10", "location": "Results, Efficacy Outcomes",
       "values": {"Esketamine group": {"events": "46", "n": "148"}, "Control group": {"events": "57", "n": "150"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 14, "form": "change_difference", "location": "Results, Efficacy Outcomes",
       "estimate": "0.32", "se": "0.49", "lower": "-0.63", "upper": "1.28", "level": "0.95", "scale": "mean_difference", "contrast": "Esketamine group minus Control group",
       "values": {"Esketamine group": {"n": "148"}, "Control group": {"n": "150"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 28, "form": "count", "definition": "EPDS ≥ 10", "location": "Results, Efficacy Outcomes",
       "values": {"Esketamine group": {"events": "53", "n": "148"}, "Control group": {"events": "55", "n": "150"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 28, "form": "change_difference", "location": "Results, Efficacy Outcomes",
       "estimate": "0.24", "se": "0.52", "lower": "-0.78", "upper": "1.26", "level": "0.95", "scale": "mean_difference", "contrast": "Esketamine group minus Control group",
       "values": {"Esketamine group": {"n": "148"}, "Control group": {"n": "150"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 42, "form": "count", "definition": "EPDS ≥ 10", "location": "Results, Efficacy Outcomes",
       "values": {"Esketamine group": {"events": "50", "n": "148"}, "Control group": {"events": "56", "n": "150"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 42, "form": "change_difference", "location": "Results, Efficacy Outcomes",
       "estimate": "-0.06", "se": "0.49", "lower": "-1.03", "upper": "0.91", "level": "0.95", "scale": "mean_difference", "contrast": "Esketamine group minus Control group",
       "values": {"Esketamine group": {"n": "148"}, "Control group": {"n": "150"}}}
    ],
    "pain": [],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2022-01-01", "end": "2023-01-01"},
    "registration": {"number": "ChiCTR2100054199", "date": null},
    "note": "After baseline, continuous EPDS is reported only as least-squares mean differences in change from baseline (MMRM with baseline EPDS as a covariate), entered as change_difference with the printed SE. The direction (esketamine minus control) is inferred from the text ('a significant decrease ... in the esketamine group compared with the control group'). Per-arm post-baseline EPDS means are in eTable 2, which is not in the source. Day 7 also reports an odds ratio of 0.55 (95% CI 0.33-0.91) and 'effect size, 0.74'. PPD is EPDS ≥ 10 (Methods and the Table's footnote). The source prints minus signs as − and, at day 42, –; both are entered as ASCII '-'. NRS pain is in eTable 3 and Figure 4 only, except movement NRS at 72 h (median 3.0 [IQR 2.0-3.0] vs 3.0 [3.0-3.5]), which falls outside the day 1-2 window. Adverse events are in eTable 5 only, with no counts in the text. Randomized: '150 each were enrolled and randomly assigned'; 2 esketamine patients refused follow-up at postpartum day 5. Enrollment dates are the Results' (assessed for eligibility between these dates); the Methods give the same."
  },
  {
    "trial": "T075",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "68", "analysed": "68"},
      "Normal saline control group": {"randomized": "68", "analysed": "68"}
    },
    "depression": [
      {"measure": "HADS-D", "day": -1, "form": "median_iqr", "location": "Table 1 (preoperative HADS-D)",
       "values": {"Esketamine group": {"median": "6", "q1": "5", "q3": "7", "n": "68"}, "Normal saline control group": {"median": "6", "q1": "5", "q3": "7", "n": "68"}}},
      {"measure": "HADS-D", "day": 1, "form": "median_iqr", "location": "Table 3 (POD1)",
       "values": {"Esketamine group": {"median": "4", "q1": "3", "q3": "5", "n": "68"}, "Normal saline control group": {"median": "5", "q1": "4", "q3": "6", "n": "68"}}},
      {"measure": "HADS-D", "day": 3, "form": "median_iqr", "location": "Table 3 (POD3)",
       "values": {"Esketamine group": {"median": "2", "q1": "1", "q3": "3", "n": "68"}, "Normal saline control group": {"median": "3", "q1": "2", "q3": "4", "n": "68"}}}
    ],
    "pain": [
      {"measure": "moderate-to-severe pain (NRS >= 4 on coughing) on POD1", "day": 1, "form": "count", "definition": "NRS ≥ 4 during coughing", "location": "Table 3 (primary outcome)",
       "values": {"Esketamine group": {"events": "35", "n": "68"}, "Normal saline control group": {"events": "47", "n": "68"}}},
      {"measure": "NRS at rest (4 h, 8 h, POD1, POD3)", "day": 1, "form": "median_iqr", "location": "Table 3 (POD1)",
       "values": {"Esketamine group": {"median": "2", "q1": "2", "q3": "4", "n": "68"}, "Normal saline control group": {"median": "3", "q1": "2", "q3": "4", "n": "68"}}},
      {"measure": "NRS at rest (4 h, 8 h, POD1, POD3)", "day": 1, "form": "mean_se", "location": "Table 5 (GEE estimated marginal means, Postop 1 d)",
       "values": {"Esketamine group": {"mean": "2.35", "se": "0.181"}, "Normal saline control group": {"mean": "3.54", "se": "0.221"}}},
      {"measure": "NRS during coughing (4 h, 8 h, POD1, POD3)", "day": 1, "form": "median_iqr", "location": "Table 3 (POD1)",
       "values": {"Esketamine group": {"median": "3", "q1": "3", "q3": "5", "n": "68"}, "Normal saline control group": {"median": "4", "q1": "3", "q3": "6", "n": "68"}}},
      {"measure": "NRS during coughing (4 h, 8 h, POD1, POD3)", "day": 1, "form": "mean_se", "location": "Table 5 (GEE estimated marginal means, Postop 1 d)",
       "values": {"Esketamine group": {"mean": "3.41", "se": "0.172"}, "Normal saline control group": {"mean": "4.79", "se": "0.234"}}},
      {"measure": "PCIA volume and hydromorphone consumed", "day": 2, "form": "median_iqr", "unit": "mg hydromorphone", "location": "Table 3 (PCIA utilization, Hydromorphone, mg)",
       "values": {"Esketamine group": {"median": "6.96", "q1": "6.24", "q3": "7.36", "n": "68"}, "Normal saline control group": {"median": "7.44", "q1": "6.74", "q3": "7.82", "n": "68"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 9",
       "values": {"Esketamine group": {"hallucination": "2", "nightmare": "6"}, "Normal saline control group": {"hallucination": "1", "nightmare": "4"}}}
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "ChiCTR2500098525", "date": "2025-03-10"},
    "note": "Tables 1-3 and 9 list Control before Esketamine. HADS-D is median (IQR); the baseline is Table 1's preoperative HADS-D. POD1 pain is entered twice: median (IQR) from Table 3, and GEE estimated marginal means with SE from Table 5 (no n printed there; Table 5 also gives 95% CIs: rest 2.00-2.71 vs 3.11-3.98, coughing 3.08-3.75 vs 4.34-5.25). The primary outcome is defined on POD1, though the Results say 'within 24 hours'. PCIA consumption (Table 3) has no stated window; it is entered as day 2 because the PCIA ran 48 hours. Hydromorphone (mg) is entered; the PCIA volume (mL) is the same consumption in volume, 87(78-92) esketamine vs 93(84.25-97.75) control. Intraoperative remifentanil and sufentanil (Table 2) are day 0 and not entered. Table 9 also gives delirium (3D-CAM, POD1-3), 6 esketamine vs 7 control, and 'Confusion and disorientation', 2 vs 3; neither is a codebook category. Per-arm randomized numbers are from the ITT table headers (n=68 each): 136 were randomized and all 136 were analysed, with no withdrawals. No enrollment dates are given."
  },
  {
    "trial": "T088",
    "source": "fulltext",
    "arms": {
      "Group A": {"randomized": "65", "analysed": "62"},
      "Group B": {"randomized": "65", "analysed": "62"},
      "Group C": {"randomized": "64", "analysed": "62"}
    },
    "depression": [
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": -1, "form": "mean_sd", "location": "Discussion, second paragraph (T1, preoperative day 1)",
       "values": {"Group A": {"mean": "6.94", "sd": "3.535"}, "Group C": {"mean": "5.94", "sd": "3.038"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 3, "form": "mean_sd", "location": "Discussion, second paragraph (T2)",
       "values": {"Group B": {"mean": "4.37", "sd": "3.370"}, "Group C": {"mean": "5.58", "sd": "3.028"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 5, "form": "mean_sd", "location": "Discussion, second paragraph (Groups B and C, mean ± SD) and third paragraph (Group A mean, no SD)",
       "values": {"Group A": {"mean": "3.37"}, "Group B": {"mean": "3.51", "sd": "2.248"}, "Group C": {"mean": "4.86", "sd": "2.631"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "mean_sd", "location": "Discussion, second paragraph (Group B, mean ± SD) and third paragraph (Groups A and C means, no SD)",
       "values": {"Group A": {"mean": "2.35"}, "Group B": {"mean": "3.00", "sd": "1.311"}, "Group C": {"mean": "4.18"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 14, "form": "mean_sd", "location": "Discussion, second paragraph (Groups A and B, mean ± SD) and third paragraph (Group C mean, no SD)",
       "values": {"Group A": {"mean": "1.88", "sd": "1.796"}, "Group B": {"mean": "2.76", "sd": "1.159"}, "Group C": {"mean": "3.17"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 30, "form": "mean_sd", "location": "Discussion, second paragraph (T6)",
       "values": {"Group A": {"mean": "1.57", "sd": "1.565"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 42, "form": "mean_sd", "location": "Discussion, second paragraph (T7)",
       "values": {"Group A": {"mean": "1.33", "sd": "1.381"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "overall", "location": "Results, adverse events paragraph (any adverse event, percentages only); Discussion, paragraph on transient side effects (psychiatric symptoms)",
       "values": {"Group A": {"any_ae": "69.4%"}, "Group B": {"any_ae": "30.6%", "psychiatric_any": "1"}, "Group C": {"any_ae": "3.2%"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-02-03", "end": "2024-05-05"},
    "registration": {"number": "ChiCTR2400080617", "date": "2024-02-02"},
    "note": "Tables 1-4 are not in the source (only 'Download CSV' links), so the EPDS values come from the Discussion: ± values from its second paragraph and means without SD from its third (MCID) paragraph. Where both give a mean they agree (day 5 B 3.51 and C 4.86, day 7 B 3.00, day 14 A 1.88 and B 2.76). The ± is not labeled; it is taken as SD, since as SEs these values would imply SDs beyond the 0-30 scale. Figure 3 plots model-adjusted means with SE error bars, and whether the Discussion's means are raw or model-adjusted is not stated. Some arm-times are not reported (B at baseline, A at day 3, B and C at days 30 and 42). The Discussion also gives Cohen's d: A vs C at days 5, 7 and 14 = 0.58, 0.82, 0.70, and A vs B at day 14 = 0.58. Group sizes are inconsistent: 65/65/64 randomized with 3/2/3 dropouts, yet 'The final analysis included 186 patients (62 per group)'. VAS and PCIA bolus results (Table 3) are not printed. Adverse events: only the overall incidence of any adverse event is printed (A 69.4%, B 30.6%, C 3.2%), entered with % signs. 'One patient in group B experienced transient psychiatric symptoms' is entered as psychiatric_any 1 for B (A and C not stated). All events occurred during surgery or in the recovery room. Enrollment is the Results' screening period; registration is 'Date of first registration: February 2nd, 2024'."
  },
  {
    "trial": "T097",
    "source": "fulltext",
    "arms": {
      "Post-ESK group": {"randomized": "40", "analysed": "37"},
      "Pre-ESK group": {"randomized": "40", "analysed": "40"},
      "Placebo group": {"randomized": "40", "analysed": "36"}
    },
    "depression": [
      {"measure": "PHQ-9", "day": -1, "form": "mean_sd", "location": "Table 2 (Preoperative)",
       "values": {"Post-ESK group": {"mean": "3.3", "sd": "1.3"}, "Pre-ESK group": {"mean": "3.4", "sd": "1.8"}, "Placebo group": {"mean": "3.3", "sd": "1.6"}}},
      {"measure": "PHQ-9", "day": -1, "form": "count", "definition": "PHQ-9 > 9", "location": "Table 3 (Preoperative, > 9 row)",
       "values": {"Post-ESK group": {"events": "0"}, "Pre-ESK group": {"events": "1"}, "Placebo group": {"events": "0"}}},
      {"measure": "PHQ-9", "day": 1, "form": "mean_sd", "location": "Table 2 (POD1)",
       "values": {"Post-ESK group": {"mean": "5.2", "sd": "2.2"}, "Pre-ESK group": {"mean": "3.9", "sd": "1.3"}, "Placebo group": {"mean": "5.7", "sd": "3.1"}}},
      {"measure": "PHQ-9", "day": 1, "form": "count", "definition": "PHQ-9 > 9", "location": "Table 3 (POD1, > 9 row)",
       "values": {"Post-ESK group": {"events": "1"}, "Pre-ESK group": {"events": "0"}, "Placebo group": {"events": "5"}}},
      {"measure": "PHQ-9", "day": 2, "form": "mean_sd", "location": "Table 2 (POD2)",
       "values": {"Post-ESK group": {"mean": "3.1", "sd": "1.4"}, "Pre-ESK group": {"mean": "2.5", "sd": "1.7"}, "Placebo group": {"mean": "3.4", "sd": "1.4"}}},
      {"measure": "PHQ-9", "day": 2, "form": "count", "definition": "PHQ-9 > 9", "location": "Table 3 (POD2, > 9 row)",
       "values": {"Post-ESK group": {"events": "0"}, "Pre-ESK group": {"events": "0"}, "Placebo group": {"events": "0"}}}
    ],
    "pain": [
      {"measure": "VAS pain score", "day": 1, "form": "mean_sd", "location": "Table 5 (On POD1)",
       "values": {"Post-ESK group": {"mean": "2.9", "sd": "1.4"}, "Pre-ESK group": {"mean": "2.4", "sd": "1.4"}, "Placebo group": {"mean": "3.5", "sd": "1.8"}}},
      {"measure": "VAS pain score", "day": 2, "form": "mean_sd", "location": "Table 5 (On POD2)",
       "values": {"Post-ESK group": {"mean": "1.5", "sd": "0.8"}, "Pre-ESK group": {"mean": "1.1", "sd": "0.7"}, "Placebo group": {"mean": "1.4", "sd": "0.8"}}},
      {"measure": "PCA pump presses (sufentanil/oxycodone pump)", "day": 1, "form": "mean_sd", "unit": "presses", "location": "Table 5 (On POD1, PCIA compression time)",
       "values": {"Post-ESK group": {"mean": "9.9", "sd": "7.9"}, "Pre-ESK group": {"mean": "7.6", "sd": "8.0"}, "Placebo group": {"mean": "13.4", "sd": "12.1"}}},
      {"measure": "PCA pump presses (sufentanil/oxycodone pump)", "day": 2, "form": "mean_sd", "unit": "presses", "location": "Table 5 (On POD2, PCIA compression time)",
       "values": {"Post-ESK group": {"mean": "13.2", "sd": "9.3"}, "Pre-ESK group": {"mean": "11.0", "sd": "10.8"}, "Placebo group": {"mean": "17.4", "sd": "15.4"}}},
      {"measure": "PCIA effective compression time", "day": 1, "form": "mean_sd", "unit": "valid presses", "location": "Table 5 (On POD1)",
       "values": {"Post-ESK group": {"mean": "8.6", "sd": "6.4"}, "Pre-ESK group": {"mean": "6.4", "sd": "5.9"}, "Placebo group": {"mean": "11.3", "sd": "8.9"}}},
      {"measure": "PCIA effective compression time", "day": 2, "form": "mean_sd", "unit": "valid presses", "location": "Table 5 (On POD2)",
       "values": {"Post-ESK group": {"mean": "11.2", "sd": "7.0"}, "Pre-ESK group": {"mean": "9.4", "sd": "8.5"}, "Placebo group": {"mean": "14.6", "sd": "11.8"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "time": "not stated (row above the POD 1 and POD 2 rows)", "location": "Table 7",
       "values": {"Post-ESK group": {"hallucination": "0"}, "Pre-ESK group": {"hallucination": "2"}, "Placebo group": {"hallucination": "0"}}},
      {"window": "postoperative", "time": "POD 1", "location": "Table 7",
       "values": {"Post-ESK group": {"dizziness": "17"}, "Pre-ESK group": {"dizziness": "16"}, "Placebo group": {"dizziness": "17"}}},
      {"window": "postoperative", "time": "POD 2", "location": "Table 7",
       "values": {"Post-ESK group": {"dizziness": "2"}, "Pre-ESK group": {"dizziness": "1"}, "Placebo group": {"dizziness": "2"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2021-09", "end": "2023-05"},
    "registration": {"number": "ChiCTR2100050874", "date": "2021-09-05"},
    "note": "Tables list Placebo, Pre-ESK, Post-ESK in that order. PHQ-9 is mean ± SD (Methods: means and SD); Table 2's significance superscripts are dropped. Table 3 gives PHQ-9 bands (0-4, 5-9, > 9) by arm and time, and only the '> 9' band is entered as counts. The source's 'depressive symptoms' (PHQ-9 ≥ 5) is the 5-9 band plus the > 9 band, which is never printed as one count; the 0-4 and 5-9 rows are in Table 3. n is not printed in Tables 2, 3, 5 or 7; analysed n per Table 1 is Placebo 36, Pre-ESK 40, Post-ESK 37. 'PCIA compression time' is entered as the design's pump presses, and 'PCIA effective compression time' (valid presses) under the source's name. Whether the POD2 counts are cumulative or per day is not stated. Table 7's hallucination row has no time (it sits above the POD 1 and POD 2 rows), and dizziness is given for POD 1 and POD 2 separately. Pre-ESK received esketamine 2 h before induction. Enrollment is from the Methods ('between September 2021 and May 2023'); the Results give no dates. The registration date, printed 05/09/2021, is read as 5 September 2021 (day/month)."
  },
  {
    "trial": "T111",
    "source": "fulltext",
    "arms": {
      "Group E (esketamine)": {"randomized": "48", "analysed": "46"},
      "Group C (saline)": {"randomized": "48", "analysed": "45"}
    },
    "depression": [],
    "pain": [
      {"measure": "VAS pain", "day": 1, "form": "median_iqr", "location": "Table 2 (24 h)",
       "values": {"Group E (esketamine)": {"median": "2", "q1": "1", "q3": "2", "n": "46"}, "Group C (saline)": {"median": "2", "q1": "2", "q3": "2", "n": "45"}}},
      {"measure": "VAS pain", "day": 2, "form": "median_iqr", "location": "Table 2 (48 h)",
       "values": {"Group E (esketamine)": {"median": "1.5", "q1": "1", "q3": "2", "n": "46"}, "Group C (saline)": {"median": "2", "q1": "1", "q3": "2", "n": "45"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "location": "Table 4 (within 48 h postoperatively)",
       "values": {"Group E (esketamine)": {"dizziness": "1", "hallucination": "1", "nightmare": "0"}, "Group C (saline)": {"dizziness": "2", "hallucination": "0", "nightmare": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": null,
    "registration": {"number": "NCT06920576", "date": null},
    "note": "Group M (magnesium sulfate, role other) is not entered. HADS-D and Zung SDS results appear only in Figures 2-3, whose descriptions give approximate values read off the charts ('~6', 'about 49'); per the codebook these are not entered, so there are no depression entries. VAS is median (IQR) from Table 2, printed as 'median (Q1, Q3)'. Rescue ketorolac (Table 3: 9 (20%) control vs 2 (4.3%) esketamine) was given in the PACU for VAS > 3, not at day 1 or 2, and is not an opioid, so it is not entered. Table 4 combines rows: 'Dizziness or headache' is entered as dizziness and 'Hallucinations or double vision' as hallucination; nightmares are printed as 0 (0%) in both arms. Randomized is 48 per group (CONSORT: 'each with 48 patients receiving allocated interventions'). Registration is ClinicalTrials.gov, 'prospectively registered ... before patient enrollment', with no date. No enrollment dates are given."
  },
  {
    "trial": "T113",
    "source": "fulltext",
    "arms": {
      "ES1 group": {"randomized": "33", "analysed": "31"},
      "ES2 group": {"randomized": "33", "analysed": "30"},
      "C group": {"randomized": "33", "analysed": "30"}
    },
    "depression": [
      {"measure": "HAMD", "day": -1, "form": "mean_sd", "location": "Table 4 (Preop)",
       "values": {"ES1 group": {"mean": "8.0", "sd": "2.1"}, "ES2 group": {"mean": "8.0", "sd": "2.7"}, "C group": {"mean": "6.8", "sd": "2.7"}}},
      {"measure": "HAMD", "day": 1, "form": "mean_sd", "location": "Table 4 (24 h postop)",
       "values": {"ES1 group": {"mean": "6.2", "sd": "2.2"}, "ES2 group": {"mean": "7.1", "sd": "2.6"}, "C group": {"mean": "9.9", "sd": "3.7"}}},
      {"measure": "HAMD", "day": 3, "form": "mean_sd", "location": "Table 4 (72 h postop)",
       "values": {"ES1 group": {"mean": "5.2", "sd": "2.4"}, "ES2 group": {"mean": "5.6", "sd": "2.6"}, "C group": {"mean": "9.0", "sd": "3.5"}}}
    ],
    "pain": [
      {"measure": "VAS at rest (24 h)", "day": 1, "form": "mean_sd", "location": "Table 5 (24 h postop)",
       "values": {"ES1 group": {"mean": "0.71", "sd": "0.82"}, "ES2 group": {"mean": "0.97", "sd": "1.00"}, "C group": {"mean": "0.62", "sd": "0.82"}}},
      {"measure": "VAS on activity (24 h)", "day": 1, "form": "mean_sd", "location": "Table 6 (24 h postop)",
       "values": {"ES1 group": {"mean": "2.87", "sd": "1.34"}, "ES2 group": {"mean": "3.17", "sd": "1.39"}, "C group": {"mean": "2.93", "sd": "1.00"}}},
      {"measure": "PCA bolus demands", "day": 1, "form": "mean_sd", "unit": "boluses", "location": "Results, PCA bolus demands paragraph",
       "values": {"ES1 group": {"mean": "4.16", "sd": "2.60"}, "ES2 group": {"mean": "5.77", "sd": "6.59"}, "C group": {"mean": "4.69", "sd": "4.38"}}}
    ],
    "adverse_events": [
      {"window": "postoperative", "time": "24 h", "location": "Table 7 (24 h AE, n (%))",
       "values": {"ES1 group": {"any_ae": "7"}, "ES2 group": {"any_ae": "5"}, "C group": {"any_ae": "8"}}},
      {"window": "postoperative", "time": "48 h", "location": "Table 7 (48 h AE, n (%))",
       "values": {"ES1 group": {"any_ae": "1"}, "ES2 group": {"any_ae": "3"}, "C group": {"any_ae": "6"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-05-01", "end": "2024-01-01"},
    "registration": {"number": "ChiCTR2300070763", "date": null},
    "note": "HAMD (HAMD-17 in the text) is mean ± SD (Methods: Mean ± SD) from Table 4, assessed 24 h preoperatively for the baseline; the Results text repeats the control values. n is not printed in Tables 4-6 (analysed per Table 3: C 30, ES1 31, ES2 30). VAS at 24 h is from Tables 5-6, with within-group superscripts dropped; 72 h is day 3 and not entered. PCA bolus demands are not in the design and are entered under the source's name at day 1, using the window from Table 2 ('Supplemental analgesia demands', 0-24 h postop). Table 7 gives only any adverse event at 24 h and 48 h; no specific events (dizziness, nightmares, hallucinations) are reported by arm. Randomized is 33 per group (Table 1); 8 were excluded before receiving the intervention. Enrollment is from the Methods' inclusion criteria (surgery between May 1, 2023 and January 1, 2024); the Results give no dates."
  }
]